New Insights in Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 May 31

PMID 35633912

Authors

Feng Yin

Zi-Hao Wu

Jin-Ping Lai

Affiliations

Soon will be listed here.

Abstract

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare epithelial neoplasms derived from pluripotent endocrine cells along the gastrointestinal tract and pancreas. GEP-NENs are classified into well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Despite overlapping morphological features, GEP-NENs vary in molecular biology, epigenetic, clinical behavior, treatment response, and prognosis features and remain an unmet clinical challenge. In this review, we introduce recent updates on the histopathologic classification, including the tumor grading and staging system, molecular genetics, and systemic evaluation of the diagnosis and treatment of GEP-NENs at different anatomic sites, together with some insights into the diagnosis of challenging and unusual cases. We also discuss the application of novel therapeutic approaches for GEP-NENs, including peptide receptor radionuclide therapy, targeted therapy, and immunotherapy with immune checkpoint inhibitors. These findings will help improve patient care with precise diagnosis and individualized treatment of patients with GEP-NENs.

Citing Articles

Predictive and prognostic nomogram models for liver metastasis in colorectal neuroendocrine neoplasms: a large population study.

Lei X, Su Y, Lei R, Zhang D, Liu Z, Li X Front Endocrinol (Lausanne). 2025; 15():1488733.

PMID: 39839478 PMC: 11746099. DOI: 10.3389/fendo.2024.1488733.

Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas.

Pavlidis E, Galanis I, Pavlidis T World J Gastrointest Oncol. 2024; 16(12):4559-4564.

PMID: 39678788 PMC: 11577359. DOI: 10.4251/wjgo.v16.i12.4559.

Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: a population-based study.

Li X, Fan Y, Tong J, Lou M Front Endocrinol (Lausanne). 2024; 15:1264952.

PMID: 38449852 PMC: 10916283. DOI: 10.3389/fendo.2024.1264952.

Risk factors for positive resection margins after endoscopic resection for gastrointestinal neuroendocrine tumors.

Han L, Li J, Liang C, Chu Y, Wang Y, Lv L Surg Endosc. 2024; 38(4):2041-2049.

PMID: 38429572 DOI: 10.1007/s00464-024-10706-0.

Gastroenteropancreatic Neuroendocrine Tumors-Current Status and Advances in Diagnostic Imaging.

Vogele D, Schmidt S, Gnutzmann D, Thaiss W, Ettrich T, Kornmann M Diagnostics (Basel). 2023; 13(17).

PMID: 37685279 PMC: 10486652. DOI: 10.3390/diagnostics13172741.

References

Shaib W, Krishna K, Kim S, Goodman M, Rock J, Chen Z . Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. Cancer Res Treat. 2015; 48(2):596-604. PMC: 4843718. DOI: 10.4143/crt.2015.029. View

Mafficini A, Scarpa A . Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev. 2019; 40(2):506-536. PMC: 6534496. DOI: 10.1210/er.2018-00160. View

Dawod M, Alonso Gordoa T, Cives M, de Mestier L, Crona J, Spada F . Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol. 2021; 22(8):73. DOI: 10.1007/s11864-021-00863-y. View

DHaese J, Tosolini C, Ceyhan G, Kong B, Esposito I, Michalski C . Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol. 2014; 20(38):13893-8. PMC: 4194570. DOI: 10.3748/wjg.v20.i38.13893. View

Lee S, Kim B, Chang H, Sohn D, Han K, Hong C . Rectal neuroendocrine and L-cell tumors: diagnostic dilemma and therapeutic strategy. Am J Surg Pathol. 2013; 37(7):1044-52. DOI: 10.1097/PAS.0b013e3182819f0f. View

Qiao X, Qiu L, Chen Y, Meng C, Sun Z, Bai C . Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord. 2014; 14:64. PMC: 4130880. DOI: 10.1186/1472-6823-14-64. View

Crona J, Gustavsson T, Norlen O, Edfeldt K, Akerstrom T, Westin G . Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol. 2015; 22 Suppl 3:S1428-35. DOI: 10.1245/s10434-014-4351-9. View

BERARDI R . Carcinoid tumors of the colon (exclusive of the rectum): review of the literature. Dis Colon Rectum. 1972; 15(5):383-91. DOI: 10.1007/BF02587418. View

Scarpa A, Chang D, Nones K, Corbo V, Patch A, Bailey P . Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017; 543(7643):65-71. DOI: 10.1038/nature21063. View

10.

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

11.

Anlauf M . Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification. Horm Metab Res. 2011; 43(12):825-31. DOI: 10.1055/s-0031-1291307. View

12.

Makuuchi R, Terashima M, Kusuhara M, Nakajima T, Serizawa M, Hatakeyama K . Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. Biomed Res. 2017; 38(1):19-27. DOI: 10.2220/biomedres.38.19. View

13.

Wang S, Parekh J, Zuraek M, Venook A, Bergsland E, Warren R . Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010; 145(3):276-80. DOI: 10.1001/archsurg.2010.10. View

14.

Howe J, Cardona K, Fraker D, Kebebew E, Untch B, Wang Y . The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017; 46(6):715-731. PMC: 5502737. DOI: 10.1097/MPA.0000000000000846. View

15.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

16.

Weber M, Fottner C . Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia. Oncol Res Treat. 2018; 41(5):306-312. DOI: 10.1159/000488996. View

17.

Milan S, Yeo C . Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2011; 24(1):46-55. DOI: 10.1097/CCO.0b013e32834c554d. View

18.

Falconi M, Eriksson B, Kaltsas G, Bartsch D, Capdevila J, Caplin M . ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016; 103(2):153-71. PMC: 4849884. DOI: 10.1159/000443171. View

19.

Una Cidon E . New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol. 2017; 9(1):4-20. PMC: 5241526. DOI: 10.4251/wjgo.v9.i1.4. View

20.

Kloppel G, Perren A, Heitz P . The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014:13-27. DOI: 10.1196/annals.1294.002. View